| Assessment Status | Rapid Review Complete |
| HTA ID | 26029 |
| Drug | Zolbetuximab |
| Brand | Vyloy® |
| Indication | Zolbetuximab (Vyloy®) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive. |
| Assessment Process | |
| Rapid review commissioned | 23/06/2026 |
| Rapid review completed | 30/07/2026 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost-effectiveness of zolbetuximab (Vyloy®) compared with the current standard of care. |